Heron Therapeutics (HRTX) reported robust financial results for Q4 2025, highlighted by significant growth in its acute care portfolio. The company’s net revenues for the full year reached $154.9 ...

Heron reported roughly $155 million in 2025 net revenues with adjusted EBITDA of $14.7 million, a ~73% gross margin and a refinancing that management said meaningfully de‑risked the capital structure.

Heron Therapeutics, Inc. (NASDAQ:HRTX) Q2 2025 Earnings Call Transcript August 8, 2025 Heron Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.02 EPS, expectations were $-0.01.

Earnings call Heron reported FY25 net product sales of $154.9M and adjusted EBITDA of $14.7M, exceeding guidance. Acute care revenues surged in Q4, with ZYNRELEF and APONVIE up 48% and 97% YoY, ...

CARY, N.C., Aug. 8, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that it has rescheduled its release of ...

Image source: The Motley Fool. Heron Therapeutics (NASDAQ:HRTX) delivered operational and financial milestones, including full-year adjusted EBITDA above guidance and net product revenue gains led by ...

Good day, and thank you for standing by, and welcome to the Heron Therapeutics Q4 2024 Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, ...

Heron Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.01772, expectations were $-0.03. Operator: Good day, and thank you for standing by. Welcome to the Heron Therapeutics Q4 2025 ...